| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45963-454-30 | 45963-454 | HUMAN PRESCRIPTION DRUG | Deferasirox | Deferasirox | TABLET, FOR SUSPENSION | ORAL | 20190322 | N/A | ANDA | ANDA203560 | Actavis Pharma, Inc. | DEFERASIROX | 125 mg/1 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-454-30) |
| 45963-455-30 | 45963-455 | HUMAN PRESCRIPTION DRUG | Deferasirox | Deferasirox | TABLET, FOR SUSPENSION | ORAL | 20190322 | N/A | ANDA | ANDA203560 | Actavis Pharma, Inc. | DEFERASIROX | 250 mg/1 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-455-30) |
| 45963-456-30 | 45963-456 | HUMAN PRESCRIPTION DRUG | Deferasirox | Deferasirox | TABLET, FOR SUSPENSION | ORAL | 20190322 | N/A | ANDA | ANDA203560 | Actavis Pharma, Inc. | DEFERASIROX | 500 mg/1 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-456-30) |